茄子直播

茄子直播 researchers find vulnerability in COVID-19 variants that reduces transmissibility

""

(illustration by NIAID)

Researchers at the University of Toronto have found that Omicron variants of the COVID-19-causing virus can be hindered in their ability to infect people by mutations in the spike protein that prevent the virus from binding to and entering cells.

The spike protein is a distinctive feature of viruses, found on their outside surface. The researchers found that mutations in this protein influence the sensitivity of Omicron variants to chemical reduction 鈥 a process that can prevent Omicron variants from spreading and could potentially be delivered to patients through aerosol therapy.

鈥淲hile infection by the Omicron variant usually leads to milder symptoms, this variant is unique in how easily it can spread,鈥 said , lead author on the study and senior research associate of , a professor at 茄子直播鈥檚 .

鈥淥ur study clearly demonstrates a significant vulnerability of Omicron to chemical reduction 鈥 one that is either not found or is much less potent in previous variants of coronavirus.鈥

The team's in the Journal of Molecular Biology.

The researchers found that Omicron-specific mutations in the virus鈥檚 spike protein reduce its ability to bind to a key receptor in host cells, called ACE2. The spike protein鈥檚 receptor-binding domain, the surface of which comes into contact with the ACE2 receptor, consists of multiple disulfide bonds. Two of these bonds, involving the C480-C488 and C379-C432 disulfides, are highly susceptible to cleavage through chemical reduction, the team showed.

""
Researchers Zhong Yao, left, and Igor Stagljar (supplied images)

The internal environment of a cell is in a naturally reduced state compared to the surface, and does not usually support disulfides bonds. In contrast, extracellular proteins and protein domains contain disulfide bonds that are oxidized, creating a structural conformation that helps them bind to receptors.

Breaking disulfide bonds changes the conformation of the proteins, so they can no longer fit into their receptors. Treating the Omicron spike protein with a reducing agent breaks the disulfide bonds at the surface, inhibiting the spike protein from binding to the ACE2 receptor.

鈥淲hile mutations, in general, have increased the transmissibility of Omicron subvariants, as well as their ability to evade the immune system, this vulnerability to disulfide cleavage presents potential target areas for treating Omicron infections,鈥 said Stagljar, who is also a professor of biochemistry and molecular genetics at 茄子直播鈥檚 .

One potential treatment method that takes advantage of Omicron鈥檚 structural vulnerability is aerosol therapy. Reducing agents can be toxic to the body at higher levels and can potentially harm non-target proteins. Aerosol therapy overcomes this obstacle by delivering the reducing agent directly to the lungs, which can tolerate a higher concentration level of the reducing agent than the rest of the body.

The researchers found that Omicron variants were particularly sensitive to an antioxidant called bucillamine, which is in a Phase 3 clinical trial by Revive Therapeutics to evaluate its safety and efficacy.

鈥淲hile Omicron is less deadly overall, it still poses a threat to older, immunocompromised and unvaccinated groups,鈥 Yao said.

鈥淚t鈥檚 helpful to understand the mechanism through which Omicron variants are transmitted between people, so that we can harness it for therapeutic treatments and be more prepared.鈥

The research was supported by the PRiME COVID-19 Task Force, COVID Relief, the Toronto COVID-19 Action Fund and the Temerty Knowledge Translation grant.

Medicine